NCM
AUTL

Nantahala Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Nantahala Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-70,300
Closed -$150K – 120
2022
Q3 		$150K Buy
+70,300
New +$208K 0.01% 107

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Nantahala Capital Management's AUTL Position: Q3 2023 in Review

Nantahala Capital Management sold out of Autolus Therapeutics (AUTL) in Q3 2023, closing a stake of 4,272,203 shares — an estimated $10.2M sold.

Nantahala Capital Management first reported a position in AUTL in Q2 2021 and held it in 9 quarters. The position peaked at $21.2M in Q4 2021. 71 funds tracked by Wall St. Rank hold AUTL as of Q3 2023.

  • Nantahala Capital Management reported no remaining Autolus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Nantahala Capital Management sold 4,272,203 Autolus Therapeutics shares in Q3 2023, an estimated $10.2M.
  • Nantahala Capital Management first reported a position in Autolus Therapeutics in Q2 2021 and held it in 9 quarters.
  • Nantahala Capital Management's Autolus Therapeutics position peaked at $21.2M in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2023.

Based on Nantahala Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.